ImmuNext Inc.

Sanofi 's growth plans for its multiple sclerosis franchise have been boosted by positive mid-stage data for the investigational anti-CD40L antibody frexalimab. The French drugmaker will be presenting

AbCellera Biologics Inc. , 4D Molecular Therapeutics LLC (4DMT) and Nanobiotix SA launched initial public offerings on 10 and 11 December that brought in a combined $774.8m. The AbCellera offering

The last week of February wasn’t an ideal time for any company to launch an initial public offering, with US stock market indices trading lower on coronavirus fears, but Passage Bio Inc. took a chan

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Bayer/Evotec Collaboration O